Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of NVA237 in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 8.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female patients age 40 years or more~* Diagnosis of Chronic Obstructive Lung Disease (COPD) (moderate to severe as classified by the Global Initiative for COPD (GOLD) Guidelines, 2008~* Smoking history of at least 10 pack-years~* Post-bronchodilator Forced Expiratory Volume in 1 second (FEV1) \<80% and ≥30% of the predicted normal value~* Post-bronchodilator FEV1/Forced Vital Capacity (FVC) \<0.7~* Symptomatic patients, according to daily electronic diary data between visit 2 (Day -8) and Visit 3 (Day 1), with a total score of 1 or more on at least 4 of the last 7 days prior to visit 3~Exclusion Criteria:~* Patients who have had a COPD exacerbation requiring systemic corticosteroids and/or antibiotics and/or hospitalization in the 6 weeks prior to the first visit~* Patients who have had a respiratory tract infection within 4 weeks prior to the first visit~* Patients with concomitant pulmonary disease~* Patients with diabetes Type I or uncontrolled diabetes Type II~* Any patient with lung cancer or a history of lung cancer~* Patients with a history of certain cardiovascular co-morbid conditions~* Patients with a history of asthma or a blood eosinophil count \>600/mm3 or onset of symptoms prior to 40 years~* Patients with eczema, known high IgE levels or a known positive skin prick test~* Patients participating in the active phase of a pulmonary rehabilitation programme~* Patients contraindicated for the treatment with anticholinergics, long and short-acting beta-2 agonists or sympathomimetic amines~* Patients with a history of alpha-1 anti-trypsin deficiency~* Patients on long term oxygen therapy (\>15hr per day)~* Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- NVA237 12.5 µg q.d. (Type: EXPERIMENTAL): NVA237 12.5 µg once daily
- NVA237 25.0 µg q.d. (Type: EXPERIMENTAL): NVA237 25.0 µg once daily
- NVA237 12.5 µg b.i.d. (Type: EXPERIMENTAL): NVA237 12.5 µg twice daily
- NVA237 50.0 µg q.d. (Type: EXPERIMENTAL): NVA237 50.0 µg once daily
- NVA237 25.0 µg b.i.d. (Type: EXPERIMENTAL): NVA237 25.0 µg twice daily
- NVA237 100.0 µg q.d. (Type: EXPERIMENTAL): NVA237 100.0 µg once daily
- NVA237 50.0 µg b.i.d. (Type: EXPERIMENTAL): NVA237 50.0 µg twice daily
- Placebo (Type: PLACEBO_COMPARATOR): Placebo to NVA237 once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).